JP2016535019A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535019A5 JP2016535019A5 JP2016525563A JP2016525563A JP2016535019A5 JP 2016535019 A5 JP2016535019 A5 JP 2016535019A5 JP 2016525563 A JP2016525563 A JP 2016525563A JP 2016525563 A JP2016525563 A JP 2016525563A JP 2016535019 A5 JP2016535019 A5 JP 2016535019A5
- Authority
- JP
- Japan
- Prior art keywords
- adenosine
- pain
- methyl
- group
- bromothien
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 35
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 17
- 229960005305 adenosine Drugs 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- -1 3-chlorothien-2-yl Chemical group 0.000 claims description 7
- 125000006242 amine protecting group Chemical group 0.000 claims description 4
- 239000003223 protective agent Substances 0.000 claims description 4
- FKKJJPMGAWGYPN-UHFFFAOYSA-N thiophen-2-ylmethanamine Chemical class NCC1=CC=CS1 FKKJJPMGAWGYPN-UHFFFAOYSA-N 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 150000003835 adenosine derivatives Chemical class 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 5
- 208000000112 Myalgia Diseases 0.000 claims 4
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- QUBQAOONZJWWHN-HPDNKFCTSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(5-chlorothiophen-2-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC1=CC=C(S1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N QUBQAOONZJWWHN-HPDNKFCTSA-N 0.000 claims 2
- NMCXSKQZGXWJCZ-PMXXHBEXSA-N (2r,3r,4s,5r)-2-[6-[(5-bromothiophen-2-yl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3SC(Br)=CC=3)=C2N=C1 NMCXSKQZGXWJCZ-PMXXHBEXSA-N 0.000 claims 2
- 102000014461 Ataxins Human genes 0.000 claims 2
- 108010078286 Ataxins Proteins 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Chemical group 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 229910052740 iodine Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 2
- DFETZYGISAXEEJ-FMZWZIECSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(2-bromothiophen-3-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound BrC=1SC=CC1CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N DFETZYGISAXEEJ-FMZWZIECSA-N 0.000 claims 1
- KLGJJZJEBMXGIA-HPDNKFCTSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(3-bromothiophen-2-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound BrC1=C(SC=C1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N KLGJJZJEBMXGIA-HPDNKFCTSA-N 0.000 claims 1
- SFALKPJPYAEKKY-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-bromothiophen-2-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound BrC=1C=C(SC=1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N SFALKPJPYAEKKY-HIDXMTOYSA-N 0.000 claims 1
- OPUWCBGREITRRH-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-bromothiophen-3-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound BrC=1C(=CSC1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N OPUWCBGREITRRH-HIDXMTOYSA-N 0.000 claims 1
- FHZXYGAZGCDZBD-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-chlorothiophen-2-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC=1C=C(SC=1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N FHZXYGAZGCDZBD-HIDXMTOYSA-N 0.000 claims 1
- NYXVWLZCIYPJGF-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-chlorothiophen-3-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC=1C(=CSC1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N NYXVWLZCIYPJGF-HIDXMTOYSA-N 0.000 claims 1
- RAVKMGSIHFLQJU-UHFFFAOYSA-N (5-bromothiophen-2-yl)methanamine Chemical compound NCC1=CC=C(Br)S1 RAVKMGSIHFLQJU-UHFFFAOYSA-N 0.000 claims 1
- DBRSLMCLMMFHEF-UHFFFAOYSA-N (5-bromothiophen-2-yl)methanol Chemical compound OCC1=CC=C(Br)S1 DBRSLMCLMMFHEF-UHFFFAOYSA-N 0.000 claims 1
- QEEXZSPDLPRZEX-UHFFFAOYSA-N (5-chlorothiophen-2-yl)methanamine Chemical compound NCC1=CC=C(Cl)S1 QEEXZSPDLPRZEX-UHFFFAOYSA-N 0.000 claims 1
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 102000007370 Ataxin2 Human genes 0.000 claims 1
- 108010032951 Ataxin2 Proteins 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- PMSLJWQPNPWCRD-IEVJCCNJSA-N ClC=1SC=CC1CNC=1C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2N=CN1.BrC1=CC(=CS1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N Chemical compound ClC=1SC=CC1CNC=1C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2N=CN1.BrC1=CC(=CS1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N PMSLJWQPNPWCRD-IEVJCCNJSA-N 0.000 claims 1
- 206010011796 Cystitis interstitial Diseases 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 206010028836 Neck pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010065016 Post-traumatic pain Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000007613 Shoulder Pain Diseases 0.000 claims 1
- 201000003622 Spinocerebellar ataxia type 2 Diseases 0.000 claims 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 239000011630 iodine Chemical group 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 claims 1
- 208000007153 proteostasis deficiencies Diseases 0.000 claims 1
- 201000003632 spinocerebellar ataxia type 7 Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- DUDAKCCDHRNMDJ-UHFFFAOYSA-N NCc1c[s]cc1 Chemical compound NCc1c[s]cc1 DUDAKCCDHRNMDJ-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894699P | 2013-10-23 | 2013-10-23 | |
| US61/894,699 | 2013-10-23 | ||
| PCT/US2014/061734 WO2015061426A1 (en) | 2013-10-23 | 2014-10-22 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535019A JP2016535019A (ja) | 2016-11-10 |
| JP2016535019A5 true JP2016535019A5 (enExample) | 2017-11-09 |
| JP6534997B2 JP6534997B2 (ja) | 2019-06-26 |
Family
ID=52993493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525563A Active JP6534997B2 (ja) | 2013-10-23 | 2014-10-22 | 神経変性疾患及び疼痛の予防及び治療における使用のための化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10301348B2 (enExample) |
| EP (1) | EP3060566B1 (enExample) |
| JP (1) | JP6534997B2 (enExample) |
| KR (1) | KR102313314B1 (enExample) |
| CN (1) | CN106414456B (enExample) |
| AU (1) | AU2014340114B2 (enExample) |
| BR (1) | BR112016008901B1 (enExample) |
| CA (1) | CA2927699C (enExample) |
| IL (1) | IL245103B (enExample) |
| MX (1) | MX367707B (enExample) |
| RU (1) | RU2695358C2 (enExample) |
| SG (1) | SG11201603063WA (enExample) |
| WO (1) | WO2015061426A1 (enExample) |
| ZA (1) | ZA201603118B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017022578A2 (pt) | 2015-05-29 | 2018-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | agentes nucleosídicos para a redução da atividade deletéria de genes que contém repetições estendidas de nucleotídeos |
| WO2018140734A1 (en) | 2017-01-27 | 2018-08-02 | Academia Sinica | Compound with analgesic effect for use in prevention and treatment of pain |
| JP2025505186A (ja) * | 2022-02-10 | 2025-02-21 | 中央研究院 | 脊髄損傷を処置する方法及びそれにおける使用のための組成物 |
| CN119630406A (zh) * | 2022-07-07 | 2025-03-14 | 周美吟 | 治疗思觉失调症的方法及用于其中的组合物 |
| EP4642452A1 (en) * | 2022-12-29 | 2025-11-05 | Academia Sinica | Method of treating sleep disruptions and composition for use therein |
| WO2024196760A1 (en) * | 2023-03-17 | 2024-09-26 | Academia Sinica | Method of treating tuberous sclerosis complex or epilepsy and composition for use therein |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8274187A (en) * | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Heteroaromatic derivatives of adenosine |
| US5034381A (en) * | 1988-01-07 | 1991-07-23 | Ciba-Geigy Corporation | 2-(substituted amino) adenosines as antihypertensives |
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| WO1992005177A1 (en) * | 1990-09-25 | 1992-04-02 | Rhone-Poulenc Rorer International (Holdings) Inc. | Compounds having antihypertensive and anti-ischemic properties |
| UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| TWI398255B (zh) | 2009-11-13 | 2013-06-11 | Academia Sinica | 結合至腺苷酸ａａ受體和腺苷酸轉運子以預防及治療神經退化疾病的雙功能化合物 |
| CA2783859A1 (en) | 2009-12-10 | 2011-06-16 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | N6-substituted adenosine derivatives and n6-substituted adenine derivatives and uses thereof |
| CA2862750C (en) * | 2012-02-09 | 2015-11-17 | Brandbumps, Llc | Decorative detectable warning panel having improved grip |
| US20150038445A1 (en) | 2012-02-11 | 2015-02-05 | Academia Sinica | Methods and compositions for treating pain |
-
2014
- 2014-10-22 CN CN201480058727.3A patent/CN106414456B/zh active Active
- 2014-10-22 WO PCT/US2014/061734 patent/WO2015061426A1/en not_active Ceased
- 2014-10-22 AU AU2014340114A patent/AU2014340114B2/en active Active
- 2014-10-22 KR KR1020167013624A patent/KR102313314B1/ko active Active
- 2014-10-22 RU RU2016118282A patent/RU2695358C2/ru active
- 2014-10-22 JP JP2016525563A patent/JP6534997B2/ja active Active
- 2014-10-22 MX MX2016005174A patent/MX367707B/es active IP Right Grant
- 2014-10-22 CA CA2927699A patent/CA2927699C/en active Active
- 2014-10-22 SG SG11201603063WA patent/SG11201603063WA/en unknown
- 2014-10-22 EP EP14855465.2A patent/EP3060566B1/en active Active
- 2014-10-22 US US15/031,711 patent/US10301348B2/en active Active
- 2014-10-22 BR BR112016008901-4A patent/BR112016008901B1/pt active IP Right Grant
-
2016
- 2016-04-13 IL IL245103A patent/IL245103B/en active IP Right Grant
- 2016-05-10 ZA ZA2016/03118A patent/ZA201603118B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535019A5 (enExample) | ||
| CA2813183C (en) | Morpholino nucleic acid derivatives | |
| US9879096B2 (en) | Process for preparation of sugammadex sodium | |
| JP7334228B2 (ja) | 細胞毒性ベンゾジアゼピン誘導体の調製方法 | |
| CN106458901A (zh) | 用于制备稠合杂环化合物的方法 | |
| JP2017538712A5 (enExample) | ||
| JP2015051994A5 (enExample) | ||
| WO2016041508A1 (zh) | 一种噁唑烷酮类化合物及其中间体的制备方法 | |
| JP2016536316A5 (enExample) | ||
| EP3083630B1 (en) | Process methods for phosphatidylinositol 3-kinase inhibitors | |
| EP3829561A1 (en) | Substituted-3h-imidazo[4,5-c]pyridine and 1h pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (enpp1) and stimulator for interferon genes (sting) modulators as cancer immunotherapeutics | |
| JP2016503391A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2018502077A5 (enExample) | ||
| JP2016537346A5 (enExample) | ||
| RU2016118282A (ru) | Соединения для предотвращения и лечения нейродегенеративных заболеваний и боли | |
| WO2015092805A1 (en) | A process for preparation of trelagliptin succinate | |
| JP2021500354A5 (enExample) | ||
| KR20170129264A (ko) | 글리코시드 화합물의 제조 방법 | |
| CN102958931B (zh) | 碳环核苷和其中使用的中间体的合成方法 | |
| KR20190020674A (ko) | 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법 | |
| CN105753944B (zh) | 达卡他韦及其衍生物的制备中间体 | |
| JP2018515527A5 (enExample) | ||
| JP2014516968A5 (enExample) | ||
| CN107074858A (zh) | 制备(2s,5r)‑6‑(苄氧基)‑7‑氧代‑1,6‑二氮杂二环[3.2.1]辛烷‑2‑羧酸钠的方法 |